MRVI Stock Overview
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.
No risks detected for MRVI from our risk checks.
Maravai LifeSciences Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$27.88|
|52 Week High||US$63.55|
|52 Week Low||US$23.16|
|1 Month Change||-18.67%|
|3 Month Change||-21.75%|
|1 Year Change||-34.85%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-6.60%|
Recent News & Updates
Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
In this article we are going to estimate the intrinsic value of Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) by...
|MRVI||US Life Sciences||US Market|
Return vs Industry: MRVI underperformed the US Life Sciences industry which returned -17.4% over the past year.
Return vs Market: MRVI underperformed the US Market which returned -18.8% over the past year.
|MRVI Average Weekly Movement||9.4%|
|Life Sciences Industry Average Movement||11.3%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: MRVI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MRVI's weekly volatility (9%) has been stable over the past year.
About the Company
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.
Maravai LifeSciences Holdings Fundamentals Summary
|MRVI fundamental statistics|
Is MRVI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRVI income statement (TTM)|
|Cost of Revenue||US$149.20m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||1.72|
|Net Profit Margin||25.22%|
How did MRVI perform over the long term?See historical performance and comparison
Is MRVI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRVI?
Other financial metrics that can be useful for relative valuation.
|What is MRVI's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does MRVI's PE Ratio compare to its peers?
|MRVI PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
SYNH Syneos Health
SHC Sotera Health
MRVI Maravai LifeSciences Holdings
Price-To-Earnings vs Peers: MRVI is good value based on its Price-To-Earnings Ratio (16.2x) compared to the peer average (42.2x).
Price to Earnings Ratio vs Industry
How does MRVI's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Earnings vs Industry: MRVI is good value based on its Price-To-Earnings Ratio (16.2x) compared to the US Life Sciences industry average (30.9x)
Price to Earnings Ratio vs Fair Ratio
What is MRVI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||16.2x|
|Fair PE Ratio||24.6x|
Price-To-Earnings vs Fair Ratio: MRVI is good value based on its Price-To-Earnings Ratio (16.2x) compared to the estimated Fair Price-To-Earnings Ratio (24.6x).
Share Price vs Fair Value
What is the Fair Price of MRVI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MRVI ($27.88) is trading above our estimate of fair value ($23.95)
Significantly Below Fair Value: MRVI is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: MRVI is poor value based on its PEG Ratio (7.2x)
Discover undervalued companies
How is Maravai LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRVI's forecast earnings growth (2.3% per year) is above the savings rate (1.9%).
Earnings vs Market: MRVI's earnings (2.3% per year) are forecast to grow slower than the US market (13.8% per year).
High Growth Earnings: MRVI's earnings are forecast to grow, but not significantly.
Revenue vs Market: MRVI's revenue is expected to decline over the next 3 years (-6.8% per year).
High Growth Revenue: MRVI's revenue is forecast to decline over the next 3 years (-6.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRVI's Return on Equity is forecast to be high in 3 years time (26.5%)
Discover growth companies
How has Maravai LifeSciences Holdings performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRVI has high quality earnings.
Growing Profit Margin: MRVI's current net profit margins (25.2%) are higher than last year (20.4%).
Past Earnings Growth Analysis
Earnings Trend: MRVI's earnings have grown significantly by 69.3% per year over the past 5 years.
Accelerating Growth: MRVI's earnings growth over the past year (190.7%) exceeds its 5-year average (69.3% per year).
Earnings vs Industry: MRVI earnings growth over the past year (190.7%) exceeded the Life Sciences industry 21%.
Return on Equity
High ROE: MRVI's Return on Equity (82.6%) is considered outstanding.
Discover strong past performing companies
How is Maravai LifeSciences Holdings's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MRVI's short term assets ($619.1M) exceed its short term liabilities ($86.7M).
Long Term Liabilities: MRVI's short term assets ($619.1M) do not cover its long term liabilities ($1.3B).
Debt to Equity History and Analysis
Debt Level: MRVI's net debt to equity ratio (15%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MRVI's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: MRVI's debt is well covered by operating cash flow (92.9%).
Interest Coverage: MRVI's interest payments on its debt are well covered by EBIT (25.1x coverage).
Discover healthy companies
What is Maravai LifeSciences Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRVI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRVI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRVI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRVI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MRVI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carl Hull (62 yo)
Mr. Carl W. Hull serves as a Director of Ortho-Clinical Diagnostics, Inc. Mr. Hull serves as an Independent Director at Ortho Clinical Diagnostics Holdings plc since 2021. Mr. Hull Co-Founder, Chief Execut...
CEO Compensation Analysis
Compensation vs Market: Carl's total compensation ($USD1.78M) is below average for companies of similar size in the US market ($USD8.23M).
Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.
Experienced Management: MRVI's management team is considered experienced (4.7 years average tenure).
Experienced Board: MRVI's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Maravai LifeSciences Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Maravai LifeSciences Holdings, Inc.
- Ticker: MRVI
- Exchange: NasdaqGS
- Founded: 2020
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$7.139b
- Market Cap: US$3.667b
- Shares outstanding: 255.21m
- Website: https://www.maravai.com
Number of Employees
- Maravai LifeSciences Holdings, Inc.
- 10770 Wateridge Circle
- Suite 200
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.